![](/images/graphics-bg.png)
Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early OncoSuppressor Gene Expression with Tissue-Specificity in Mice
المؤلفون المشاركون
Hortobágyi, Tibor
Gergely, Péter Attila
Murnyák, Balázs
Bencze, János
Kurucz, Andrea
Varjas, Timea
Gombos, Katalin
المصدر
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-12، 12ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-02-07
دولة النشر
مصر
عدد الصفحات
12
التخصصات الرئيسية
الملخص EN
Tyrosine kinases play crucial roles in cellular development and tumorigenesis.
Tyrosine kinase inhibitors (TKIs) are effective and widely used drug molecules in targeted cancer therapies.
Altered expressions of protooncogenes and tumor suppressor genes after DMBA (7,12-dimethylbenz[a]anthracene) treatment have been described as early markers of tumor induction; however their tissue-specific effects remain still unclear.
Our study was aimed at examining the short-term possible antineoplastic and chemopreventive effects of a TKI compound (imatinib mesylate) on a DMBA-induced mouse tumor model.
In addition, we also investigated the tissue-specific expressions of Hras, Kras, Myc, and Trp53 genes in the brain, bone marrow, spleen, liver, abdominal lymph nodes, thymus, lungs, and kidneys, respectively.
24 hours after the imatinib mesylate injection, we observed significant Kras downregulation in the bone marrow and lung of the DMBA-treated mice.
Moreover, the mRNA expression of Myc was also found to be decreased significantly in the spleen.
Interestingly, while Trp53 expression was significantly increased in the lung, it was decreased in the other tissues.
However, there was also a tendency in the decreased Myc level in the bone marrow, brain, kidneys, lungs, and lymph nodes and in the decreased Hras level in the bone marrow, kidneys, and lungs, although no significant differences were observed.
Our findings indicate rapid tissue-specific impact of imatinib mesylate on DMBA-induced gene expression in vivo, supporting the chemopreventive potential of imatinib mesylate in cancer.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Gergely, Péter Attila& Murnyák, Balázs& Bencze, János& Kurucz, Andrea& Varjas, Timea& Gombos, Katalin…[et al.]. 2019. Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early OncoSuppressor Gene Expression with Tissue-Specificity in Mice. BioMed Research International،Vol. 2019, no. 2019, pp.1-12.
https://search.emarefa.net/detail/BIM-1128062
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Gergely, Péter Attila…[et al.]. Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early OncoSuppressor Gene Expression with Tissue-Specificity in Mice. BioMed Research International No. 2019 (2019), pp.1-12.
https://search.emarefa.net/detail/BIM-1128062
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Gergely, Péter Attila& Murnyák, Balázs& Bencze, János& Kurucz, Andrea& Varjas, Timea& Gombos, Katalin…[et al.]. Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early OncoSuppressor Gene Expression with Tissue-Specificity in Mice. BioMed Research International. 2019. Vol. 2019, no. 2019, pp.1-12.
https://search.emarefa.net/detail/BIM-1128062
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1128062
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)